Hear from Our Experts
An insightful exploration into the HBV landscape, how ARCUS gene editing is unique among other genetic modalities in development, details regarding the upcoming PBGENE-HBV clinical trial, and more.
HBV Currently Lacks a Curative Treatment
Hepatitis B is a leading cause of morbidity in the US and death globally, with no current curative options
> 1,000,000
cHBV infections in the US
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/us-map-min.png)
> 300 million
cHBV infections globally
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/globe-min.png)
15% to 40% of patients
with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths.
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/patient-icon-min1.png)
Current HBV treatments require life-long chronic treatment that may result in viral suppression by reducing circulating HBV DNA, but these therapies do not eradicate HBV cccDNA and therefore rarely lead to functional cure.
PBGENE-HBV:
ARCUS Uniquely Targets HBV
by eliminating cccDNA and inactivating integrated HBV DNA
Current Therapeutic Strategies
are limited and do not target the root cause of disease – viral replication
HBV Mechanism of Infection
Reasons to Believe in Precision’s Approach for HBV
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/icon1-min3.png)
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/icon2-min3.png)
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/icon3-min3.png)
![](https://precisionbiosciences.com/wp-content/uploads/2024/04/icon4-min2.png)